Cell lines

Huh7-Luc HCV genotype 1b replicon cell line

Preparation method

The solubility of this compound in DMSO is >18.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 � for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 � for several months.

Reacting condition

0.1 ~ 1000 nM; 72 hrs

Applications

In Huh7-Luc HCV genotype 1b replicon cell line, Simeprevir exhibited dose-dependent inhibitory effects, with the EC50 and EC90 values of 8 nM and 24 nM, respectively. Meanwhile, Simeprevir did not show significant effect on the cellular ribosomal protein RPL13A transcript level. According to the immunoblot analysis of replicon cell lysates collected after 72 hrs, NS5B expression was dose-dependently reduced, but α-tubulin expression was not suppressed.

Animal models

Male SD rats

Dosage form

2 mg/kg, i.v. or 20 mg/kg, p.o.

Applications

In male SD rats, Simeprevir was well distributed in the liver, with a high liver/plasma ratio after oral administration reaching 32. The T1/2 value for oral administration of Simeprevir was 2.8 hrs. When Simeprevir was given intravenously, Simeprevir showed a low clearance (Cl = 0.505 L/h/kg) associated with a low Vdss (0.490 L/kg).

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Simeprevir is a potent inhibitor of HCV NS3/4A protease with Ki value of 0.36 nM [1].
The hepatitis C virus (HCV) NS3/4A protease is a serine protease encoded by HCV and is responsible for cleavage at four sites of the HCV polyprotein. It is essential for viral replication [1].
In Huh-7-Rep cells, Simeprevir inhibited HCV replication with EC50 of 7.8 nM [1]. In the Huh7-Luc HCV genotype 1b replicon cell line, Simeprevir inhibited HCV replication with EC50 and EC90 values of 8 nM and 24 nM respectively in a dose dependent way [2].
In ninety-two naive, HCV genotype 1-infected patients, treatment with Simeprevir (50 or 100 mg QD) for 12 or 24 weeks and peginterferon ��-2a/ribavirin (PegIFN��-2a/RBV) for 24 or 48 weeks or PegIFN ��-2a/RBV for 48 weeks lonely (PR48 group), RNA reductions in the 4 week were -5.2,-5.2 and-2.9 log10IU/mL for Simeprevir 50 mg combined, 100 mg combined and PR48 groups, respectively, which suggested Simeprevir reduced HCV RNA more rapidly and substantially. Also, Simeprevir increased the virologic response rates [3].
References:
[1]. Raboisson P, de Kock H, Rosenquist A, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett, 2008, 18(17): 4853-4858.
[2]. Lin TI, Lenz O, Fanning G, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother, 2009, 53(4): 1377-1385.
[3]. Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-na?ve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol, 2014, 49(1): 138-147.